Unfortunately, the worst side effects of replacement therapy, i.e., the development of antibodies neutralizing the activity of infused FVIII, so far affects 26.8% and 44.5% of hemophilia A patients treated with pdFVIII or rFVIII concentrates, respectively [11]. The gene discussed is F8; the disease is hemophilia A.